Kindstar Globalgene Technology, Inc. (HK:9960)
:9960
Want to see HK:9960 full AI Analyst Report?
Top Page
Kindstar Globalgene Technology, Inc.
(9960)
Select Model
Select Model
Rating:49Neutral
Price Target:
HK$1.00
▼(-14.53% Downside)
Action:Reiterated
Date:04/30/26
The score is held back primarily by sustained revenue contraction and continued net losses, despite a relatively strong low-leverage balance sheet and an encouraging swing to positive operating and free cash flow in 2025. Technicals and valuation signals are broadly neutral, offering limited near-term support.
Positive Factors
Conservative balance sheet
Kindstar’s low debt-to-equity and sizable equity base provide durable financial resilience, reducing bankruptcy and refinancing risk. This capital conservatism supports discretionary investments, M&A optionality, and the ability to withstand industry headwinds without forcing dilutive financing.
Negative Factors
Sustained revenue contraction
Three consecutive years of revenue decline indicate persistent demand or pricing challenges in core markets. Reduced top-line scale pressures fixed-cost absorption, hinders investment ROI, and makes operational leverage harder to achieve, constraining durable earnings recovery prospects.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Kindstar’s low debt-to-equity and sizable equity base provide durable financial resilience, reducing bankruptcy and refinancing risk. This capital conservatism supports discretionary investments, M&A optionality, and the ability to withstand industry headwinds without forcing dilutive financing.
Read all positive factors
Kindstar Globalgene Technology, Inc. (9960) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$1.20B
Dividend Yield2.02%
Average Volume (3M)956.95K
Price to Earnings (P/E)―
Beta (1Y)0.69
Revenue Growth0.69%
EPS Growth-1.39%
CountryHK
Employees3,011
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)-0.06
Shares Outstanding1,041,309,900
10 Day Avg. Volume603,200
30 Day Avg. Volume956,950
Financial Highlights & Ratios
PEG Ratio-6.54
Price to Book (P/B)0.37
Price to Sales (P/S)1.07
P/FCF Ratio22.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Kindstar Globalgene Technology, Inc. Business Overview & Revenue Model
Company Description
Kindstar Global (Beijing) Technology, Inc. provides medical esoteric testing services to hospitals in China. Its services include medical research, drug trial, and translational medicine research services for physicians, medical science and techno...
How the Company Makes Money
null...
Kindstar Globalgene Technology, Inc. Financial Statement Overview
Summary
Income Statement
36
Negative
Balance Sheet
70
Positive
Cash Flow
48
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 933.57M | 927.57M | 967.26M | 1.39B | 930.67M |
| Gross Profit | 411.38M | 439.56M | 451.13M | 603.05M | 485.77M |
| EBITDA | -95.69M | -117.24M | 126.38M | 150.72M | -1.39B |
| Net Income | -58.74M | -54.59M | 41.29M | 75.46M | -1.45B |
Balance Sheet | |||||
| Total Assets | 3.76B | 3.77B | 3.67B | 3.73B | 3.19B |
| Cash, Cash Equivalents and Short-Term Investments | 1.56B | 1.66B | 2.03B | 2.00B | 2.15B |
| Total Debt | 438.12M | 398.36M | 194.29M | 199.86M | 18.19M |
| Total Liabilities | 969.17M | 950.51M | 774.23M | 871.62M | 464.15M |
| Stockholders Equity | 2.73B | 2.78B | 2.87B | 2.83B | 2.72B |
Cash Flow | |||||
| Free Cash Flow | 43.60M | -179.57M | -189.65M | -102.90M | -220.23M |
| Operating Cash Flow | 91.17M | -44.12M | -14.78M | 21.41M | 68.03M |
| Investing Cash Flow | -36.85M | -1.21B | 854.92M | -1.35B | -666.06M |
| Financing Cash Flow | -39.49M | 144.63M | -82.83M | 97.64M | 1.59B |
Kindstar Globalgene Technology, Inc. Technical Analysis
Neutral
1.17
Price Trends
1.15
Positive
1.17
Negative
1.29
Negative
Market Momentum
-0.01
Positive
52.40
Neutral
56.41
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:9960, the sentiment is Neutral. The current price of 1.17 is above the 20-day moving average (MA) of 1.14, above the 50-day MA of 1.15, and below the 200-day MA of 1.29, indicating a neutral trend. The MACD of -0.01 indicates Positive momentum. The RSI at 52.40 is Neutral, neither overbought nor oversold. The STOCH value of 56.41 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:9960.
Kindstar Globalgene Technology, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | HK$129.27B | 29.67 | 9.11% | ― | 26.35% | 28.38% | |
56 Neutral | HK$6.48B | 41.92 | 0.62% | ― | -9.81% | -72.56% | |
54 Neutral | HK$1.49B | 117.78 | 0.48% | 0.49% | -2.63% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | HK$1.00B | -3.94 | -15.15% | ― | 18.62% | 44.24% | |
49 Neutral | HK$1.20B | -16.99 | -2.11% | 2.02% | 0.69% | -1.39% | |
49 Neutral | HK$6.16B | 16.86 | -10.66% | 2.38% | -5.73% | -442.94% |
* Healthcare Sector Average
HK:9960
Kindstar Globalgene Technology, Inc.
1.10
-0.24
-17.91%
HK:1951
Jinxin Fertility Group Ltd.
2.26
-0.48
-17.52%
HK:3886
Town Health International Medical Group Ltd.
0.22
-0.02
-7.63%
HK:6078
Hygeia Healthcare Holdings Co., Ltd.
10.34
-5.38
-34.22%
HK:6618
JD Health International, Inc.
40.58
-0.57
-1.39%
HK:2453
Concord Healthcare Group Co., Ltd. Class H
1.28
-4.69
-78.56%
Kindstar Globalgene Technology, Inc. Corporate Events
Kindstar Globalgene Sets 2026 AGM to Renew Mandates and Board Line-Up
Apr 24, 2026
Kindstar Globalgene Technology, Inc. has convened its 2026 annual general meeting as a virtual event on 5 June 2026 to review the audited financial statements for the year ended 31 December 2025 and to decide on a series of key governance matters....
Kindstar Narrows Loss as It Bets on Oncology and CRO Growth Amid Industry Headwinds
Mar 29, 2026
Kindstar Globalgene reported 2025 revenue of RMB933.6 million, up 0.65% year on year, as it navigated industry-wide adjustment in China’s third-party medical testing sector amid tighter medical insurance cost controls and increased mutual re...
Kindstar Globalgene Reshapes Board and Committees to Bolster Governance
Mar 29, 2026
Kindstar Globalgene Technology has announced an updated composition of its board of directors, effective March 27, 2026, confirming Dr. Huang Shiang as chairman and chief executive officer alongside a mix of executive, non-executive and independen...
Kindstar Globalgene Declares Final 2025 Dividend of HKD 0.095 Per Share
Mar 29, 2026
Kindstar Globalgene Technology, Inc. has declared a final ordinary cash dividend of HKD 0.095 per share for the financial year ended 31 December 2025, payable in Hong Kong dollars. The dividend is subject to shareholder approval on 5 June 2026, wi...
Kindstar Sets March 27 Board Meeting to Approve 2025 Results and Consider Final Dividend
Mar 17, 2026
Kindstar Globalgene Technology, Inc. has scheduled a board meeting for March 27, 2026, to review and approve the group’s consolidated final results for the financial year ended December 31, 2025, and to authorize their publication. The board...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.